Jaka jest cena za Exopharm Limited (EX1)

Cena za Exopharm Limited (EX1) wynosi $0.00700343

Jaka jest kapitalizacja rynkowa dla Exopharm Limited (EX1)

Kapitalizacja rynkowa dla Exopharm Limited (EX1) wynosi $637.31K

Exopharm Limited (EX1) Dywidendy

Exopharm Limited is an Australian clinical-stage firm dedicated to developing groundbreaking therapeutics utilizing extracellular vesicles (EVs). Its core technologies include an extracellular vesicle positioning system (EVPS), which facilitates the precise targeting of exosomes by attaching specific molecules to their surface, guiding them to particular tissues or cell types. Another innovation is oligonucleotide packing, designed to optimize therapeutic delivery by preferentially loading specific RNA molecules into exosomes as medicinal cargo. Additionally, Exopharm employs ligand-based exosome affinity purification for effectively isolating and refining exosomes from biological fluids such as blood and cell culture media. The company's engineered EV product portfolio features Fortrexo CoV, aimed at treating SARS-CoV-2 infections; Cognevo, developed for neurodegenerative diseases; and PlexoDox, intended for cancer treatment. Exopharm Limited also maintains a research collaboration with Showa Denko Materials Co., Ltd. The company was founded in 2013 and is headquartered in Melbourne, Australia.

Rok	Dywidenda (skorygowana o podziały akcji)	Zmień
Za mało danych dla podanych dat.

Rok

Dywidenda (skorygowana o podziały akcji)

Zmień

Za mało danych dla podanych dat.

Rok	Dywidenda	Zmień
Za mało danych dla podanych dat.

Rok

Dywidenda

Zmień

Za mało danych dla podanych dat.

Firma	Liczba wypłat dywidend	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	29.00%	BE

Firma

Liczba wypłat dywidend

Kraj